Novo Nordisk rolls out lower prices for Ozempic and Wegovy

medicalxpress - People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

AI Summary: In a bid to ease the financial burden on self‐pay patients, Novo Nordisk has unveiled deep price cuts for its flagship GLP-1 drugs, Ozempic and Wegovy. The new pricing strategy comes amid intensifying market pressures and aims to broaden access to these critical therapies for weight management and type 2 diabetes.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Compounding Pharmacy Sues Lilly and Novo Nordisk / 4 months

Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 6 months

Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 6 months

Trump Administration Secures Lower Obesity Drug Prices / 6 months

Medicare unveils new option for covering weight‑loss drugs for seniors / 22 days

Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines / 2 months

Novo Nordisk legal action threat over copycat Wegovy pill / 3 months